executive leadership team
Sandy Macrae, M.B., Ch.B., Ph.D.
Chief Executive Officer
Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology.
Dr. Macrae received his B.S. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.
Executive Vice President, Corporate Strategy
Stéphane Boissel has served as Executive Vice President of Corporate Strategy since joining Sangamo in October 2018. Prior to joining Sangamo, he served as CEO of TxCell SA, a CAR-Treg company based in Valbonne, France, which Sangamo acquired in 2018. Mr. Boissel is an experienced biotech professional who brings over 25 years of leadership experience across corporate finance, strategy and business development. Prior to his appointment as CEO of TxCell in April 2015, he served as CEO of Genclis, a molecular diagnostics company. From 2002 to 2010, he served as CFO then EVP and CFO of Innate Pharma SA, and from 2010 to 2014 he served as EVP and CFO of Trangene SA. Earlier in his career, Mr. Boissel worked in investment banking for Lazard, where he focused on principal investment in France, Singapore and Hong Kong.
Mr. Boissel completed his undergraduate work in management and finance at the University of Lyon and Paris-Dauphine in France and received his M.B.A. from the University of Chicago.
Adrian Woolfson, B.M., B.Ch., Ph.D.
Executive Vice President, Research & Development
Adrian Woolfson, BM, BCh, PhD, has served as Sangamo’s Executive Vice President of Research & Development since January 2019. Dr. Woolfson has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Most recently, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the development of the company’s off-the-shelf and personalized neoantigen vaccine and oncolytic virus strategy. Prior to Nouscom, Dr. Woolfson served as Global Clinical Leader, Early and Late Stage Immuno-Oncology/Hematology at Pfizer Inc. in New York, and was responsible for defining Pfizer’s hematology immuno-oncology strategy and building its immuno-oncology hematological malignancies portfolio. Prior to that he was the Global Lead for Pfizer’s SMO inhibitor glasdegib, which received FDA approval in 2018. From 2007 to 2013, Dr. Woolfson held roles of increasing responsibility at Bristol-Myers Squibb, including Global Medical Lead for a first-in-human CDC7 inhibitor and selective JAK2 inhibitor.
Dr. Woolfson completed his post-graduate training in internal medicine at Addenbrooke’s Hospital Cambridge in the UK. He holds a BM BCh degree in Clinical Medicine from Oxford University and completed his PhD in molecular immunology at Cambridge University. He was the Charles and Katherine Darwin Research Fellow at Darwin College Cambridge, and a Wellcome Trust Clinical Research Fellow. He completed his doctoral and post-doctoral work in the laboratory of Nobel Prize winner and inventor of monoclonal antibodies Dr César Milstein in the Division of Protein and Nucleic Acid Chemistry at the MRC Laboratory of Molecular Biology in Cambridge, UK.
Chief Financial Officer & Secretary
Kathy Yi serves as Executive Vice President, Chief Financial Officer & Secretary of Sangamo. Ms. Yi was formerly with Novartis Pharmaceuticals where she served as Head of Finance, Inhalation Technical Research & Development, responsible for the financial management of technical R&D organizations in California and Switzerland. Prior to joining Novartis, she was with Life Technologies Corp. from 2007 to 2014, during which time she held financial management positions of increasing seniority, including Finance Leader, Corporate FP&A. Prior to joining Life Technologies, Ms. Yi held various positions in finance at Intel Corp., from 2001 to 2007. She began her career as a Process/Project Engineer at Bechtel Corp., a leading global engineering, construction and project management company.
Ms. Yi received a B.S. degree in Chemical Engineering from the University of California at Berkeley and an M.B.A. degree from Columbia Business School.
Edward Conner, M.D.
Chief Medical Officer
Edward Conner, M.D. has served as Senior Vice President and Chief Medical Officer since November 2016. He has over 10 years of industry experience in early and late stage clinical development in a broad range of disease areas including rare diseases, oncology and infectious diseases. Prior to joining Sangamo, Dr. Conner served as Vice President, Clinical Sciences at Ultragenyx Pharmaceuticals, a biopharmaceutical company developing novel products for the treatment of rare and ultra-rare diseases. Prior to joining Ultragenyx, he served as Senior Medical Director at BioMarin Pharmaceuticals Inc., where he led protocol development and regulatory interaction for its global phase 3 program in Pompe disease. From 2008 to 2013, Dr. Conner served as Medical Director at Genentech and was the clinical science team leader of two product candidates, including Xolair®, which is now a commercial drug product.
He completed his Internal Medicine residency training at the University of Michigan and was a fellow in Clinical Immunology & Allergic Diseases at Johns Hopkins School of Medicine. He received a B.S. in Biology, cum laude, from Duke University and his M.D. from the University of California, San Francisco.
R. Andrew Ramelmeier, Ph.D.
Chief Manufacturing & Quality Officer
R. Andrew “Andy” Ramelmeier, PhD, currently serves as Senior Vice President and Chief Manufacturing & Quality Officer and is responsible for Technical Operations at Sangamo, including manufacturing, quality supply chain, and process and analytical development. Dr. Ramelmeier has 25 years of experience in the biopharmaceutical industry, developing and transferring biological processes, designing and building manufacturing facilities, and directing contract manufacturers as well as internal manufacturing operations. Prior to joining Sangamo in January 2018, he served as Senior Vice President, Technical Operations at Portola Pharmaceuticals, Inc., where he was responsible for tech transfer, bulk and drug product manufacturing, technical support and supply chain of Portola’s pipeline products. From 2006 to 2014, Dr. Ramelmeier served as Vice President, Manufacturing, Process Sciences and Facilities at BioMarin, overseeing multiple commercial biologics products, clinical pipeline, and facilities in Novato, CA, and Shanbally, Ireland. Earlier in his career, he held roles of increasing responsibility at Johnson & Johnson and Merck.
Prior to joining industry, Dr. Ramelmeier conducted post-doctoral work in Germany. He received a B.S. in Chemical Engineering from Johns Hopkins and his Ph.D. in Chemical Engineering from the University of California, Berkeley.
Edward Rebar, Ph.D.
Chief Technology Officer
Edward Rebar, Ph.D., has served as Senior Vice President and Chief Technology Officer since July 2018. Dr. Rebar joined Sangamo in 1998, and over the last 20 years has led the development of the Company's zinc finger protein technology platform. He has authored over 60 publications relating to the development of customized DNA binding proteins and nucleases for genome editing. Prior to joining Sangamo, he was a post-doctoral fellow at the University of California, Berkeley.
Dr. Rebar earned his B.S. in Biochemistry from Rutgers University and his Ph.D. in Biophysics and Structural Biology from MIT.
Jason Fontenot, PH.D.
Senior Vice President, Cell Therapy
Jason Fontenot, Ph.D., has served as Sangamo’s Senior Vice President of Cell Therapy since March 2019. Dr. Fontenot oversees Sangamo's engineered cell therapy portfolio, including a proprietary chimeric antigen receptor regulatory T cells (CAR-Tregs) pipeline, a partnership with Sanofi focused on ex vivo genome editing programs in hemoglobinopathies, and a partnership with Kite, a Gilead Company, to develop autologous and allogeneic CAR-T cell therapies in oncology. Dr. Fontenot has an extensive background in cell therapy and drug development, having previously served as Chief Scientific Officer at Immusoft, Head of Exploratory Research at Juno Therapeutics, and for nearly a decade as a group leader in the immunology department at Biogen.
Dr. Fontenot has expertise in lymphocyte biology, cell engineering and immune-mediated disease. His seminal work on regulatory T cells and FOXP3 conducted with Alexander Rudensky and colleagues transformed the study of immune regulation and produced some of the most highly cited immunology publications of the last 20 years.
Dr. Fontenot conducted post-doctoral work at Rockefeller University in New York City. He received his Ph.D. in Immunology from the University of Washington in Seattle working in the laboratory of Alexander Rudensky.
Nathalie Dubois-Stringfellow, Ph.D.
Vice President, Product Development and Management
Nathalie Dubois-Stringfellow, Ph.D., has served as Vice President, Product Development and Management since January 2015 and oversees the development and execution of project team strategy for Sangamo’s ZFP therapeutic programs in hemophilia, lysosomal storage disorders, hemoglobinopathies, HIV and Huntington’s disease. She has over 20 years of experience implementing and managing preclinical and clinical development of biologic therapies in oncology, as well as immune, infectious and genetic diseases. Dr. Dubois-Stringfellow joined Sangamo in January 2011 as Senior Director, Project Management. Prior to joining Sangamo, she held various positions in Discovery Research, Preclinical Research, Project Management, Clinical Development, and Portfolio Management at Chiron Corp., Bayer Corp., Signature Biosciences, Inc. and most recently XOMA LLC, where she served as Senior Director, Preclinical Portfolio and Alliance Management.
Dr. Dubois-Stringfellow was a post-doctoral fellow at the University of North Carolina, Chapel Hill, where she studied angiogenesis and tumorigenesis in transgenic mice and cell culture systems. She received her M.S. in Genetics and Immunology, and her Ph.D. in Human Genetics from the Université Pierre et Marie Curie in Paris, France.
Vice President, General Manager of Europe
Duncan McKay has served as Vice President and General Manager of Europe since January 2018. He has over 30 years of experience in the pharmaceutical industry across R&D and commercial strategy, business development, risk management, compliance and communications. Throughout his career Mr. McKay obtained regulatory approval for over 10 new medicines for patients in major markets. Prior to joining Sangamo, he held various leadership positions at GlaxoSmithKline (GSK), from 2000 to 2015, in Emerging Markets R&D, Oncology R&D and Clinical Operations of Europe. While at GSK, Mr. McKay developed a high value portfolio of patented and non-patented medicines and created access for several million new patients, played an integral role in the design and creation of Oncology R&D within the organization and successfully led pivotal registration clinical studies for three new oncology medicines. Earlier in his career, he worked in clinical development at Beecham Research Laboratories and SmithKline Beecham, legacy companies of GSK.
Mr. McKay received a B.S. in Biochemistry from the University of Surrey and his M.B.A. from Henley Business School in the United Kingdom.
Vice President, Corporate Communications and Investor Relations
McDavid Stilwell has served as Vice President, Corporate Communications and Investor Relations since November 2016. He has over 20 years of relevant experience across various business functions, including communications, investor relations, business development and financial analysis. Prior to joining Sangamo, Mr. Stilwell served as Vice President, Corporate Communications, Investor Relations & Business Development at Orexigen Therapeutics, Inc. From 2005 to 2012 he served as Director, Business Development, Corporate Communications and Financial Analysis at GTx, Inc., a development stage biopharmaceutical company. Earlier, Mr. Stilwell worked for five years as a Senior Investment Analyst for Shadwell Capital LLC, a hedge fund. Mr. Stilwell began his career as a journalist, first as a newspaper reporter and later as an executive editor of an investor newsletter covering financial services industry mergers and acquisitions.
Mr. Stilwell received a B.A. in Liberal Arts from St. John’s College, Annapolis, Maryland, and a M.B.A. from Harvard Business School.
Board of Directors
H. Stewart Parker
Chairwoman of the Board
H. Stewart Parker has been a member of our Board of Directors since June 2014. Ms. Parker has over 30 years of experience in the biotechnology industry. She served as the chief executive officer of The Infectious Disease Research Institute (IDRI), a not-for-profit global health research institute from March 2011 to December 2013. In 1992, Ms. Parker founded Targeted Genetics Corporation, a publicly traded Seattle-based biopharmaceutical company formed to develop gene-based treatments for acquired and inherited diseases that became a world leader in AAV gene therapy. She held the position of President and CEO and was a member of its board of directors from the company's inception until November 2008. Prior to founding Targeted Genetics, Ms. Parker served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. From February 1991 to January 1993, Ms. Parker served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry. She currently serves as a member of the board of directors for several for-profit and non-profit companies including C3 Jian Inc, Oncogenex Technologies Inc and IDRI and on the advisory boards of the University of Washington Foster School of Business and College of Arts & Sciences. Ms. Parker received her B.A. and M.B.A. from the University of Washington.
Executive Vice President and CBO of Horizon Pharma, plc
Robert F. Carey has served as a member of Sangamo's Board of Directors since June 2016. Mr. Carey currently serves as Executive Vice President and Chief Business Officer of Horizon Pharma, plc, a biopharmaceutical company with nine commercialized medicines though its orphan, rheumatology and primary care units. He also serves as a member of the Board of Directors of Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of personalized immuntherapies for the treatment of cancer and infectious diseases. Before joining Horizon Pharma, he served as managing director and head of the healthcare investment banking group at JMP Securities LLC from March 2013 to March 2014. Prior to that, Mr. Carey served as a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities International, Inc. He has also held roles at Shearson Lehman Hutton and Ernst & Whinney. Mr. Carey received a B.S. in Accounting from the Univesity of Notre Dame.
Stephen Dilly, M.B.B.S., Ph.D.
Former CEO of Aimmune Therapeutics
Stephen G. Dilly, M.B.B.S., Ph.D., has served as a member of our Board of Directors since March 2010. From May 2014 – June 2018, he served as CEO of Aimmune Therapeutics. Prior to that, from December 2011 to December 2012 Dr. Dilly was CEO of PhotoThera, Inc., a medical device company with a product in Phase III clinical trials for the treatment of ischemic stroke. From 2006 to 2011, Dr. Dilly served as President and Chief Executive Officer and a member of the Board of Directors of APT Pharmaceuticals, Inc. From 2003 to 2006, he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003, he held various management positions at Genentech Inc., including Vice President of Development Sciences from 2002 to 2003. From 1988 to 1998, Dr. Dilly held various management positions in drug development with SmithKline Beecham in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly currently serves as a member of the Advisory Board of Physic Ventures and the National Board of Advisors of the UC Davis Health System. In 1982, Dr. Dilly earned his M.B.B.S., the equivalent of an M.D. in the U.S., from the University of London in the U.K. and received his Ph.D. in Cardiac Physiology from University of London in 1988.
Roger Jeffs, Ph.D.
Formerly co-CEO of United Therapeutics Corp.
Roger Jeffs, Ph.D., has served as a member of Sangamo's Board of Directors since June 2017. Prior to his retirement in 2016, Dr. Jeffs served as President and co-CEO of United Therapeutics Corp., where he worked for 18 years, joining the company in its start-up phase in 1998 as Director, Research, Development and Medical and serving as President and Chief Operating Officer from 2001 to 2014. He has over 25 years of experience in the biopharmaceutical industry in R&D, clinical development, regulatory and medical affairs. While at United Therapeutics, Dr. Jeffs led the clinical development, regulatory approval and commercialization of six rare disease products and managed the commercial effort that led to a greater than 20% compound annual growth rate (CAGR) and $1.5 billion annual revenue run rate. Prior to joining United Therapeutics, he held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co. Dr. Jeffs currently also serves as a member of the board of directors of Albireo Pharma, Axsome Therapeutics and Dova Pharmaceuticals. He received a B.A. in Chemistry from Duke University and his Ph.D. in Pharmacology from the University of North Carolina School of Medicine.
Sandy Macrae, M.B., Ch.B., Ph.D.
Chief Executive Officer
Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr. Macrae received his B.Sc. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.
Steven Mento, Ph.D.
President and CEO of Conatus Pharmaceuticals, Inc.
Steven Mento has served as a member of our Board of Directors since May, 2005. He is President and Chief Executive Officer of Conatus Pharmaceuticals Inc. From 1997 to 2005 he was President and CEO of Idun Pharmaceuticals and prior to that, from 1982 to 1992, Dr. Mento held various positions at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. In January of 1992, he joined Viagene, Inc. as Vice President of Research and Development. Dr. Mento was responsible for directing the company's transition from basic research through initiation of the first company sponsored Phase I and Phase II clinical trials in the emerging field of gene therapy. In October of 1995, Chiron Corporation acquired Viagene, Inc., and renamed the company Chiron Viagene, Inc. Dr. Mento served as President of Chiron Viagene, Inc. and Vice President of Chiron Corporation until August of 1997. As President, Dr. Mento had overall responsibility for gene therapy research, product development, QA/ QC, GMP manufacturing as well as general administration functions at Chiron Viagene. Dr. Mento currently serves on the Boards of BIOCOM, the Biotechnology Organization (BIO), the BIO Health Section Governing Body, the BIO ECS Governing Body, the Donald P. Shiley BioSciences Center at SDSU Scientific Advisory Board, and Cal State San Marcos Advisory Council. Dr. Mento holds Bachelor of Arts, Master of Science, and Ph.D. degrees in microbiology from Rutgers University. He did his post-doctoral fellowship in somatic cell genetics at the University of Toronto.
Managing Partner of Life Sciences Advisory
Saira Ramasastry has served as a member of our Board of Directors since June 2012. Since April 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a company that she founded to provide strategic advice and business development solutions for life science companies. From 1999 to 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions (M&A), strategic and capital markets transactions. Prior to joining Merrill Lynch she served as a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry currently serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson's Research, the board of directors of Pain Therapeutics and Repros Therapeutics, and lead business advisor for the European Prevention of Alzheimer's Dementia (EPAD) consortium. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University as well as an M. Phil. in Management Studies from the University of Cambridge, where she is a guest lecturer for the Bioscience Enterprise Programme and serves on the Cambridge Judge Business School Advisory Council.
Karen Smith, M.D., Ph.D., M.B.A.
Formerly Executive Vice President, Global Head R&D, and CMO of Jazz Pharmaceuticals
Karen Smith, M.D., Ph.D., M.B.A., has served as a member of Sangamo’s Board of Directors since June 2018. Dr. Smith has over 20 years of biopharmaceutical industry experience in the United States, Europe, Canada and Asia. She has overseen more than 50 clinical trials and more than 20 regulatory approvals leading to global product launches of small molecules, biologics and devices. Most recently, she served as Executive Vice President, Global Head R&D, and Chief Medical Officer of Jazz Pharmaceuticals, Inc. Prior to joining Jazz in 2015, Dr. Smith served as Senior Vice President, Global Medical Affairs and Global Dermatology Head for Allergan plc. From 2008 to 2011, she held leadership positions in External Medical Relations and Global Development at AstraZeneca, and from 2002 to 2008 she held various senior management and clinical roles with Bristol-Myers Squibb, including Head of U.S. Clinical Operations. Dr. Smith currently is a member of the Board of Directors of Acceleron Pharma and a Board Advisor for the Australian Philanthropic 'Eliminate Cancer' Initiative.
Dr. Smith received a B.App.Sc. in Biotechnology and a B.Sc. in Haematology from Curtin University of Technology, an M.D. from the University of Warwick, her Ph.D. in Oncology Molecular Genetics from the University of Western Australia, an M.B.A. from the University of New England in Australia, and a Master of Laws (L.L.M.) in Health Law from the University of Salford.
Joseph S. Zakrzewski
Formerly Chairman and CEO of Amarin Pharmaceuticals
Joseph S. Zakrzewski has served as a member of Sangamo's Board of Directors since June 2017. Mr. Zakrzewski has over 25 years of experience in the biopharmaceutical industry with senior leadership experience in R&D, supply chain and manufacturing operations, business development and commercialization. From 2010 through 2013, he was Chairman and CEO of Amarin Pharmaceuticals, where he led the development and commercialization of the company's first product, Vascepa. Mr. Zakrzewski previously served as a Venture Partner with Orbimed Advisors, a venture capital firm, and as Chairman, President and CEO of Xcellerex, a privately held company focused on the commercialization of its proprietary manufacturing technology for biotherapeutics and vaccines. Earlier, he served as COO of Reliant Pharmaceuticals before its acquisition by GlaxoSmithKline in 2007 and held various executive positions at Eli Lilly & Company in the areas of R&D, manufacturing, finance and business development. Mr. Zakrzewski currently serves as a member of the board of directors of various public and private companies, including Acceleron Pharma, Amarin Pharmaceuticals Insulet Corporation and Onxeo SA where he serves as Chairman. Mr. Zakrzewski received a B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University, and an M.B.A. in Finance from Indiana University.